Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
ID: 333432Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $225K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/333432

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs." This initiative aims to support formative research and pilot-testing of innovative interventions that address HIV prevention and treatment specifically for populations affected by substance use. The focus is on developing strategies that are feasible, acceptable, and safe, utilizing a combination of behavioral, social, and structural approaches to enhance health outcomes in marginalized communities. Applicants can seek funding of up to $450,000 over a maximum of three years, with proposals due by January 7, 2025. For further information, interested parties can contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-21-205-Full-Announcement.html
    PA-21-205.html
    The Department of Health and Human Services, through the National Institutes of Health, has issued a Funding Opportunity Announcement (FOA) titled "Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs." This initiative encourages formative research and pilot-testing of interventions for drug users that address HIV prevention and treatment. The focus is on the feasibility, acceptability, and safety of innovative strategies combining behavioral, social, and structural approaches to combat HIV, particularly among populations significantly impacted by substance use. Applications must propose clinical trials and can seek up to $450,000 over a maximum of three years. The FOA emphasizes the need for interventions targeting the specific challenges faced by marginalized groups, enhancing access to services, and integrating substance use and HIV treatment approaches. The proposal deadlines extend through January 7, 2025, reinforcing NIH's commitment to improving health outcomes within high-risk communities and facilitating research leading to scalable interventions against HIV.
    Similar Opportunities
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at expanding HIV prevention strategies among populations affected by alcohol use. This initiative encourages research projects that explore the relationship between alcohol consumption and HIV risk behaviors, focusing on areas such as Pre-exposure Prophylaxis (PrEP) utilization, Treatment as Prevention (TasP), and the integration of preventive intervention strategies. The program is particularly significant for addressing health disparities among high-risk groups, including men who have sex with men (MSM) and women with high-risk partners. The NIH anticipates funding between $2 million for 2 to 4 awards, with a project period of up to five years. Interested applicants can submit their proposals through the NIH ASSIST system or Grants.gov, and should direct inquiries to grantsinfo@nih.gov. The application deadline is May 7, 2026.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at expanding the HIV/AIDS prevention toolkit among populations impacted by alcohol use. This grant seeks to support research that integrates effective prevention and treatment interventions while addressing the behavioral and biological risks associated with alcohol consumption, particularly among high-risk groups. The initiative is crucial for informing the design of future clinical trials focused on HIV prevention, with an anticipated funding amount of approximately $1.5 million for 2-4 awards. Interested applicants, including higher education institutions and community organizations, must submit their proposals by September 7, 2025, and can find additional information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at testing innovative care models that integrate HIV, addiction, and primary care services. This initiative seeks to address gaps in comprehensive health service delivery for individuals at heightened risk for HIV or living with HIV and substance use disorders, emphasizing the need for replicable and sustainable interventions. The program is critical for enhancing service delivery to vulnerable populations and aligns with national public health goals to combat the HIV epidemic in the United States. Interested applicants can apply for a share of the $2 million funding by March 20, 2025, and should direct inquiries to grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html for more details.